Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Related Keywords

,Transforming Largeb Cell Lymphoma ,Novel Agents ,Treatment Paradigm ,Dlbcl ,Lymphoma ,Largeb Cell Lymphoma ,Car T ,Cart Cell ,Cart Cell Therapy ,Cart Cell Therapy Lymphoma ,Cart Cell Therapy Largeb Lymphoma ,Patients With Lbcl ,Patients With Largeb Cell Lymphoma ,Mechanisms Of Action ,Clinical Applications ,